What does Monopar Therapeutics Inc. do?
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is…
What is Monopar Therapeutics Inc.'s P/E and P/B ratio?
Monopar Therapeutics Inc. has a P/E ratio of -33.0 and a P/B ratio of 3.72.
What is Monopar Therapeutics Inc.'s debt-to-equity ratio?
Monopar Therapeutics Inc. has a debt-to-equity ratio of 0.00.
How much does Monopar Therapeutics Inc. owe compared with what it owns?
Monopar Therapeutics Inc. owes $0.03 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Monopar Therapeutics Inc.'s Positivity rank?
Monopar Therapeutics Inc. is ranked #3,872 of 6,774 companies globally and #1,795 of 4,000 in United States on PositoAI, with a Positivity Score of 20,135.
Does Monopar Therapeutics Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Monopar Therapeutics Inc..
Where can I read the latest news about Monopar Therapeutics Inc.?
Recent headlines about Monopar Therapeutics Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Monopar Therapeutics Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Monopar Therapeutics Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.